$BVS Income Statement | Understand Stock

$BVS

$14.42 -$0.30 (2.04%) Close

$BVS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations and Comprehensive Income (Loss)

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net sales
Cost of sales (including depreciation and amortization of $41,251, $41,882 and $48,503, respectively)
Gross profit
Selling, general and administrative expense
Research and development expense
Restructuring costs
Change in fair value of contingent consideration
Depreciation and amortization
Impairment of assets
Impairment of goodwill
Loss on disposals
Impairment of variable interest entity assets
Operating income (loss)
Interest expense, net
Loss on extinguishment
Other expense (income)
Other expense
Income (loss) before income taxes
Income tax (benefit) expense, net
Net income (loss) from continuing operations
Loss from discontinued operations, net of tax
Net income (loss)
Loss attributable to noncontrolling interest
(Income) loss attributable to noncontrolling interest - continuing operations
Loss attributable to noncontrolling interest - discontinued operations
Total loss attributable to noncontrolling interest
Net income (loss) attributable to Bioventus Inc.
Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment
Change in foreign currency translation adjustments
Change in the fair value of cash flow hedges
Comprehensive income (loss)
Comprehensive loss attributable to noncontrolling interest
Comprehensive (income) loss attributable to noncontrolling interest - continuing operations
Comprehensive loss attributable to noncontrolling interest - discontinued operations
Total comprehensive loss attributable to noncontrolling interest

Comprehensive income (loss) attributable to Bioventus Inc.
Income (loss) per share of Class A common stock from:
Continuing operations, basic (in dollars per share)
Discontinued operations, basic (in dollars per share)
Basic income (loss) per Class A common stock (in dollars per share)
Continuing operations, diluted (in dollars per share)
Discontinued operations, diluted (in dollars per share)
Diluted income (loss) per Class A common stock (in dollars per share)
Weighted-average shares of Class A common stock outstanding:
Basic (in shares)
Diluted (in shares)

Comments